ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
First patients dosed with Fasenra in three dermatology trials
April 26, 2021With the addition of the new dermatology trials, Fasenra is now being evaluated in nine different indications associated with eosinophilic immune dysfunction. -
Bertilimumab Granted Orphan Drug Designation for the Treatment of Bullous Pemphigoid
August 22, 2018Immune Pharmaceuticals, Inc., a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation
Pharma Sources Insight January 2025
